Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13...

|About: Endologix Inc (ELGX)|By:, SA News Editor

Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13 revenue guidance to $128-134M. The company now projects a wider net loss than previously expected however and also says it is temporarily suspending enrollment in its Ventana U.S. IDE clinical trial. (PR)